THROMBOPOIETIN, THE MPL LIGAND, IS ESSENTIAL FOR FULL MEGAKARYOCYTE DEVELOPMENT

被引:288
作者
KAUSHANSKY, K
BROUDY, VC
LIN, N
JORGENSEN, MJ
MCCARTY, J
FOX, N
ZUCKERFRANKLIN, D
LOFTONDAY, C
机构
[1] NYU,DEPT MED,NEW YORK,NY 10016
[2] ZYMOGENET INC,SEATTLE,WA 98102
关键词
D O I
10.1073/pnas.92.8.3234
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The development of megakaryocytes (MKs) from their marrow precursors is one of the least understood aspects of hematopoiesis. Current models suggest that early-acting MK colony-stimulating factors, such as interleukin (IL) 3 or c-kit ligand, are required for expansion of hematopoietic progenitors into cells capable of responding to late-acting MK potentiators, including IL-6 and IL-11. Recently, the Mpl ligand, or thrombopoietin (Tpo), has been shown to display both MK colony-stimulating factor and potentiator activities, at potencies far greater than that of other cytokines. In light of these findings, we tested the hypothesis that Tpo is absolutely necessary for MK development. In this report we demonstrate that neutralizing the biological activity of Tpo eliminates MK formation in response to c-kit ligand, IL-6, and IL-11, alone and in combination, but that these reagents only partially reduce MK formation in the presence of combinations of cytokines including IL-3. However, despite the capacity of IL-3 to support the proliferation and initial stages of MK differentiation, elimination of Tpo prevents the full maturation of IL-3-induced MK. These data indicate that two populations of MK progenitors can be identified: one that is responsive to IL-3 but can fully develop only in the presence of Tpo and a second that is dependent on Tpo for both proliferation and differentiation. Thus, our results strongly suggest that Tpo is the primary regulator of MK development and platelet production.
引用
收藏
页码:3234 / 3238
页数:5
相关论文
共 37 条
  • [1] AVRAHAM H, 1992, BLOOD, V79, P365
  • [2] BATLEY TD, 1994, CELL, V77, P1117
  • [3] BRANDT JE, 1994, BLOOD, V83, P1507
  • [4] BRIDDELL RA, 1991, BLOOD, V78, P2854
  • [5] BRIDDELL RA, 1992, BLOOD, V79, P332
  • [6] RECOMBINANT HUMAN ERYTHROPOIETIN - PURIFICATION AND ANALYSIS OF CARBOHYDRATE LINKAGE
    BROUDY, VC
    TAIT, JF
    POWELL, JS
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1988, 265 (02) : 329 - 336
  • [7] LEUKEMIA INHIBITORY FACTOR AND INTERLEUKIN-11 PROMOTE MATURATION OF MURINE AND HUMAN MEGAKARYOCYTES INVITRO
    BURSTEIN, SA
    MEI, RL
    HENTHORN, J
    FRIESE, P
    TURNER, K
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1992, 153 (02) : 305 - 312
  • [8] DAI CH, 1991, BLOOD, V78, P2493
  • [9] EFFECTS OF THE RECOMBINANT HEMATOPOIETIC GROWTH-FACTORS INTERLEUKIN-3, INTERLEUKIN-6, STEM-CELL FACTOR, AND LEUKEMIA INHIBITORY FACTOR ON THE MEGAKARYOCYTIC DIFFERENTIATION OF CD34+ CELLS
    DEBILI, N
    MASSE, JM
    KATZ, A
    GUICHARD, J
    BRETONGORIUS, J
    VAINCHENKER, W
    [J]. BLOOD, 1993, 82 (01) : 84 - 95
  • [10] DEGABRIELE G, 1967, BRIT J HAEMATOL, V13, P202